Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
671.0 GBX -29.00 ( 4.14%)
Last update at 2026-10-27T16:35:00Z
VOLUME
11144
Market Cap
62.04M

Momentum Score

…

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
668.86
Low
730.00
High
52 Week Price Range
124.00
Low
1800.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
700.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
2.92
ROE
-631.11%
Net Debt
2.46M
ROCE
-175.37%
Diluted EPS TTM
-2.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -5.63M -6.70M -3.99M -5.11M -2.10M
Minority interest 0.01M 0.01M 0.01M 0.01M -0.02M
Net income -5.62M -6.69M -4.35M -7.52M -2.12M
Selling general administrative 4.74M 4.91M 0.94M 1.40M 0.62M
Selling and marketing expenses - 4.91M - - 0.00M
Gross profit -0.64M -0.65M -2.60M -0.28M -0.35M
Reconciled depreciation 0.64M 0.65M 0.20M 0.13M 0.11M
Ebit -5.35M -6.38M 4.00M -2.70M -2.15M
Ebitda -4.71M -5.73M -3.42M -2.56M -1.96M
Depreciation and amortization 0.64M 0.65M -7.42M 0.14M 0.20M
Operating income -5.73M -5.56M 4.00M -2.70M -2.15M
Other operating expenses 5.73M 5.56M 5.53M 2.83M 2.22M
Interest expense 0.27M 0.32M 0.00M 2.60M 0.03M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.02M 0.09M 0.01M 0.02M 0.00M
Net interest income -0.25M -0.23M 0.01M -2.58M -0.03M
Income tax expense - -0.01M 0.36M 2.41M 0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 5.09M 4.91M 2.93M 2.55M 1.87M
Cost of revenue 0.64M 0.65M 2.60M 0.28M 0.35M
Total other income expense net 0.10M -1.14M -7.98M -2.41M 0.06M
Net income from continuing ops -5.63M -6.70M -3.99M -5.11M -2.10M
Net income applicable to common shares - - - -5.10M -2.08M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4.21M 6.11M 7.09M 8.52M 2.66M
Intangible assets 0.48M 0.47M 0.44M 0.44M 0.25M
Other current assets 0.67M 0.92M - 0.30M 0.10M
Total liab 3.36M 3.32M 3.85M 0.35M 1.79M
Total stockholder equity 0.90M 2.82M 3.28M 8.19M 0.89M
Deferred long term liab - - - - 0.22M
Other current liab -0.37M -0.20M 0.05M 0.05M 0.05M
Common stock 0.04M 11.76M 9.80M 9.80M 4.34M
Capital stock 0.04M 11.76M 9.80M 9.80M 4.34M
Retained earnings -35.58M -23.80M -17.11M -13.13M -8.04M
Other liab - - - - 0.00M
Good will - 0.03M - - -
Other assets - - - 0.14M 0.22M
Cash 0.16M 1.25M 2.53M 6.84M 1.81M
Total current liabilities 1.16M 0.65M 0.75M 0.35M 1.78M
Current deferred revenue - -0.00M - - -
Net debt 2.46M 1.70M 0.89M -6.83M -0.18M
Short term debt 0.85M 0.55M 0.32M 0.01M 1.62M
Short long term debt - - 0.00M 0.00M 1.58M
Short long term debt total 2.62M 2.95M 3.42M 0.01M 1.63M
Other stockholder equity 35.37M 19.94M 10.59M 11.53M 4.59M
Property plant equipment - - - 0.80M 0.27M
Total current assets 0.84M 2.17M 2.59M 7.14M 1.92M
Net tangible assets - - - 7.75M 0.64M
Net receivables 0.01M 0.00M 0.00M 0.30M 0.06M
Long term debt - - - - 0.00M
Accounts payable 0.68M 0.30M 0.37M 0.30M 0.11M
Accumulated other comprehensive income 1.07M -5.07M - - -0.21M
Common stock total equity - - - - 4.34M
Non currrent assets other 0.17M 0.15M 0.14M 0.14M 0.22M
Non current assets total 3.37M 3.94M 4.50M 1.38M 0.75M
Capital lease obligations 2.62M 2.95M 3.42M 0.01M 0.05M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.00M -0.03M -0.42M -0.94M -0.17M
Change to liabilities - - 0.00M 0.30M -0.04M
Total cashflows from investing activities -0.02M -0.03M - -0.94M -0.17M
Net borrowings - - - -3.22M 0.42M
Total cash from financing activities 3.08M 4.45M -0.11M 8.78M 3.21M
Change to operating activities - - - - 0.00M
Net income -5.62M -6.69M -3.99M -5.11M -2.10M
Change in cash -1.09M -1.29M -4.31M 5.03M 1.31M
Begin period cash flow 1.25M 2.53M 6.84M 1.81M 0.50M
End period cash flow 0.16M 1.25M 2.53M 6.84M 1.81M
Total cash from operating activities -4.12M -6.11M -2.91M -2.63M -1.80M
Issuance of capital stock 3.71M 5.09M - 0.00M 3.18M
Depreciation 0.64M 0.65M 0.20M 0.13M 0.11M
Other cashflows from investing activities -0.01M 0.09M - -0.12M 0.00M
Change to account receivables -0.00M 0.00M - -0.20M -0.02M
Sale purchase of stock - - - - 3.18M
Other cashflows from financing activities -0.64M -0.64M -0.42M 11.96M 0.03M
Change to netincome - - 0.63M 2.24M 0.23M
Capital expenditures 0.01M 0.12M 0.43M 0.82M 0.17M
Change in working capital 0.60M -0.83M 0.24M 0.10M -0.06M
Stock based compensation 0.34M 0.00M 0.02M 0.15M 0.36M
Other non cash items 0.26M 0.77M 0.62M 2.12M 0.03M
Free cash flow -4.13M -6.22M -3.34M -3.45M -1.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
HEMO
Hemogenyx Pharmaceuticals PLC		 -29.00
4.14%		 671.00 - - - 8.49 -3.62
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 -12.04

Profile*

Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

6 Heddon Street, London, United Kingdom, W1B 4BT

44 79 0917 7311

https://hemogenyx.com

16

Name Title Year Born
Dr. Vladislav Sandler Ph.D. Co-Founder, CEO & Director NA
Ms. Alexis M. Sandler J.D. Independent Co-Founder & Non-Exec. Director NA
Mr. Andrew Wright Financial Controller & Company Sec. NA
Dr. Koen Van Besien M.D., Ph.D. Clinical Advisor & Medical Director NA
Dr. Vladislav Sandler Ph.D. Co-Founder, CEO & Director 1965
Ms. Alexis M. Sandler J.D. Independent Co-Founder & Non-Executive Director 1976
Mr. Ben Harber Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…